Literature DB >> 30242498

Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve.

Rossana Di Paola1, Simone Garzon2, Sara Giuliani1, Antonio Simone Laganà3, Marco Noventa4, Francesca Parissone1, Carlotta Zorzi1, Ricciarda Raffaelli1, Fabio Ghezzi3, Massimo Franchi1, Stefano Zaffagnini1.   

Abstract

PURPOSE: To evaluate the potential application of a nomogram based on woman's age and ovarian reserve markers as a tool to optimize the follicle-stimulating hormone (FSH) starting dose in intrauterine insemination (IUI) cycles.
METHODS: We conducted a retrospective analysis enrolling 179 infertile women undergoing controlled ovarian stimulation (COS), followed by IUI. Each woman received an FSH starting dose according to clinical decision. After collecting data about COS and IUI procedures, we calculated the FSH starting dose according to the nomogram. The main outcomes measured were women's baseline characteristics, COS, and clinical outcomes.
RESULTS: The FSH starting dose calculated by the nomogram was significantly lower than the one actually prescribed (p < 0.001), in only 14.8% of the cycles nomogram calculated a higher starting dose. When gonadotropin dose was decreased during COS, and similarly in case of hyper-response (more than two follicles ≥ 16 mm retrieved), the FSH starting dose calculated by the nomogram would have been lower in most of the cases (81.8% and 48.8%, respectively). Conversely, when gonadotropin dose was increased during COS and in case of low ovarian response (no follicle ≥ 16 mm retrieved), the FSH starting dose calculated by the nomogram would have been lower in most of the cases (64.7% and 100%, respectively); in these groups median anti-Müllerian hormone (AMH) level was 5.62 ng/mL.
CONCLUSIONS: The application of this nomogram in IUI cycles would lead to a more tailored FSH starting dose and improved cost-effectiveness, although in PCOS women, particularly the ones with high AMH, it does not seem adequate.

Entities:  

Keywords:  Anti-Müllerian hormone; Controlled ovarian stimulation; Follicle-stimulating hormone; Intrauterine insemination; Nomogram; Starting dose

Mesh:

Substances:

Year:  2018        PMID: 30242498     DOI: 10.1007/s00404-018-4906-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  33 in total

1.  In vitro Maturation of Oocytes with Consecutive Clinical Pregnancy after Accidental Premature Ovulation Induction-A Rescue Strategy in Art.

Authors:  S Findeklee; J Hachenberg; K Kienast
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

Review 2.  Falsely elevated serum estradiol in woman of reproductive age led to unnecessary intervention and delayed fertility opportunity: a case report and literature review.

Authors:  Jing Zhang; Liangzhi Xu; Lin Qiao
Journal:  BMC Womens Health       Date:  2022-06-16       Impact factor: 2.742

3.  Rescue In Vitro Maturation in Polycystic Ovarian Syndrome Patients Undergoing In Vitro Fertilization Treatment who Overrespond or Underrespond to Ovarian Stimulation: Is It A Viable Option? A Case Series Study.

Authors:  Muhammad Fatum; Marie Eve Bergeron; Caroline Ross; Anni Ding; Ayesha Bhevan; Karen Turner; Tim Child
Journal:  Int J Fertil Steril       Date:  2020-07-15

4.  COMPARISON OF MORPHOMETRIC AND MORPHOLOGY OOCYTES AFTER IN VITRO MATURATION BETWEEN HEALTHY WOMEN AND PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME.

Authors:  A Allahveisi; E Yousefian; M J Rezaie; B Nikkhoo
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jul-Sep       Impact factor: 0.877

5.  Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle.

Authors:  Neeta Singh; Yogita Dogra; Monika Saini; Matheswari Govindarajan
Journal:  BMJ Case Rep       Date:  2020-01-26

6.  The Clinical Efficacy of Three Different Follicle-Stimulating Hormones for Follicle Growth and Development in Long-Protocol Controlled Ovarian Hyperstimulation Treatment.

Authors:  Xi-Qian Zhang; Li-Jia Zhang; Xiu-Lan Zhu; Hong Xu; Yan-Qun Luo; Li Yao; Qian-Wen Huang; Ying-Qi Nong; Wen-Juan Liu; Feng-Hua Liu
Journal:  Drug Des Devel Ther       Date:  2021-08-16       Impact factor: 4.162

7.  Minimal ovarian stimulation is an alternative to conventional protocols for older women according to Poseidon's stratification: a retrospective multicenter cohort study.

Authors:  Mauro Cozzolino; Gustavo Nardini Cecchino; Ernesto Bosch; Juan Antonio Garcia-Velasco; Nicolás Garrido
Journal:  J Assist Reprod Genet       Date:  2021-04-13       Impact factor: 3.357

8.  Association of birth weight with functional ovarian reserve during menacme estimated by serum concentration of anti-Müllerian hormone.

Authors:  Maria L S Lima; Gustavo S Romão; Heloisa Bettiol; Marco Antonio Barbieri; Rui A Ferriani; Paula A Navarro
Journal:  Sci Rep       Date:  2019-05-30       Impact factor: 4.379

9.  Progesterone elevation on the day of hCG trigger has detrimental effect on live birth rate in low and intermediate ovarian responders, but not in high responders.

Authors:  Ze Wu; Yunhua Dong; Yanping Ma; Yonggang Li; Lei Li; Na Lin; Yunxiu Li; Li Zhuan; Yun Bai; Xi Luo; Xiaomin Kang
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

10.  Response to ovulation induction treatments in women with polycystic ovary syndrome as a function of serum anti-Müllerian hormone levels.

Authors:  Stylianos Vagios; Caitlin R Sacha; Karissa C Hammer; Irene Dimitriadis; Kaitlyn E James; Charles L Bormann; Irene Souter
Journal:  J Assist Reprod Genet       Date:  2021-05-01       Impact factor: 3.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.